Literature DB >> 18489645

Chromophobe renal cell carcinoma and 'capsulomas' with acquired cystic disease of the kidney in a long-term hemodialysis patient.

Keisuke Nishihara1, Kohei Shomori, Yoji Nagashima, Naoto Kuroda, Hirotaka Nagamatsu, Hisao Ito.   

Abstract

Patients receiving long-term hemodialysis tend to develop renal cell carcinoma (RCC). Among such cases, chromophobe RCC and so-called 'capsulomas' are rarely reported. Here, we report a case of a Japanese woman in her early 70s, who developed both renal lesions after 17 years of hemodialysis. The patient received radical nephrectomy for enlarging renal mass. Grossly, the resected kidney showed a dominant tumor and small-sized subcapsular nodules. Histologically, two types of neoplasm, chromophobe RCC and 'capsuloma', existed with acquired cystic disease of the kidney. Chromophobe RCC had eosinophilic cytoplasm with perinuclear halos, and some tumor cells showed oncocytic features. Hale's colloidal iron staining showed a weakly positive cytoplasmic reaction. Immunohistochemistry was diffusely positive for cytokeratin 7, but negative for vimentin in the tumor cells. 'Capsulomas' were multiple subcapsular nodules composed almost entirely of smooth muscle-like cells with immunoreactivity for melanosome-associated antigen detected by HMB-45.

Entities:  

Mesh:

Year:  2008        PMID: 18489645     DOI: 10.1111/j.1442-2042.2008.02039.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  2 in total

Review 1.  Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas.

Authors:  Qiu Rao; Qiu-Yuan Xia; Liang Cheng; Xiao-Jun Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis.

Authors:  Wenhua Xu; Wenna Yang; Chunfeng Wu; Xiaocong Ma; Haoyu Li; Jinghui Zheng
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.